BREAKING: Novo Nordisk (NVO) says its investigational obesity drug CagriSema delivered about 21% average weight loss at lower doses in the phase 3 REDEFINE 9 trial — 21.0% on the 1.0 mg dose and 20.7% on the 1.7 mg dose at 68 weeks, versus just 2.0% on placebo, in 309 adults with overweight or obesity.
The results, the first phase 3 test of CagriSema below the maximum 2.4 mg dose, were presented at ObesityWeek 2026 in Washington, D.C. and published in The Lancet Diabetes & Endocrinology. Novo has already filed the 2.4 mg version with the FDA, with a decision expected in Q4 2026 — CagriSema itself is still investigational and not yet approved.
#NovoNordisk #NVO #Stocks #Pharma #StockMarket
The results, the first phase 3 test of CagriSema below the maximum 2.4 mg dose, were presented at ObesityWeek 2026 in Washington, D.C. and published in The Lancet Diabetes & Endocrinology. Novo has already filed the 2.4 mg version with the FDA, with a decision expected in Q4 2026 — CagriSema itself is still investigational and not yet approved.
#NovoNordisk #NVO #Stocks #Pharma #StockMarket
120 Views